Genetic cancer vaccines: current status and perspectives

Expert Opinion on Biological Therapy
L Aurisicchio, G Ciliberto

Abstract

The recent approval of the first therapeutic cancer vaccine by the US Regulatory Agency represents a breakthrough event in the history of cancer treatment. The past scepticism towards this type of therapeutic intervention is now replaced by great expectations. The field is now moving towards the development of alternative vaccination technologies, which are capable of generating stronger, more durable and efficient immune responses against specific tumour-associated antigens (TAAs) in combination with cheaper and more standardised manufacturing. In this context, genetic vaccines are emerging among the most promising methodologies. Several evidences point to combinations of different genetic immunisation modalities (heterologous prime/boost) as a powerful approach to induce superior immune responses and achieve greater clinical efficacy. In this review, we provide an overview of the current status of development of genetic cancer vaccines with particular emphasis on adenoviral vector prime/DNA boost vaccination schedules. We believe that therapeutic genetic cancer vaccines have the strong potential to become an established therapeutic modality for cancer in next coming years, in a manner similar to what have now become monoclona...Continue Reading

References

Aug 1, 1992·Current Opinion in Immunology·N Murray, A McMichael
Jul 11, 1998·Journal of Virology·S RoyM Kaleko
Aug 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J L MarshallJ Schlom
Apr 15, 2003·The Journal of Gene Medicine·Manuela CappellettiElena Fattori
Jul 5, 2003·Virology·P Seshidhar ReddySheila Connelly
Oct 11, 2003·Protein Expression and Purification·Anders Fuglsang
Nov 12, 2005·Journal of Virology·Matthieu Perreau, Eric J Kremer
Nov 18, 2005·Advances in Genetics·Margaret A Liu, Jeffrey B Ulmer
Nov 22, 2005·Vaccine·Dinesh S Bangari, Suresh K Mittal
Dec 2, 2005·Gene Therapy·N TatsisH C J Ertl
Nov 4, 2006·The Journal of Immunology : Official Journal of the American Association of Immunologists·Stefania CaponeAntonella Folgori
Feb 17, 2007·International Journal of Cancer. Journal International Du Cancer·Luigi AurisicchioNicola La Monica
Mar 10, 2007·Current Cancer Drug Targets·Anne Moon Crompton, David H Kirn
Jul 4, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Robert J DursoWilliam C Olson
Oct 22, 2008·Human Gene Therapy·Federica MoriLuigi Aurisicchio
Feb 26, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Luigi AurisicchioNicola La Monica
Mar 24, 2009·Current Opinion in Immunology·Steven A Rosenberg, Mark E Dudley
Jun 9, 2009·Current Opinion in Immunology·Shan Lu
Jun 11, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Daniela PeruzziLuigi Aurisicchio
Jun 11, 2009·Molecular Therapy : the Journal of the American Society of Gene Therapy·Marcio O Lasaro, Hildegund C J Ertl
Jun 25, 2009·Expert Opinion on Investigational Drugs·Ravi A MadanJames L Gulley
Aug 4, 2009·Expert Opinion on Biological Therapy·Sridhar DharmapuriLuigi Aurisicchio
Dec 1, 2009·Vaccine·Daniela PeruzziLuigi Aurisicchio

❮ Previous
Next ❯

Citations

Jan 22, 2014·Human Gene Therapy·Ronald G Crystal
Nov 8, 2013·Expert Review of Vaccines·Pier-Luigi LolliniPatrizia Nanni
Sep 27, 2013·Expert Review of Vaccines·Luigi AurisicchioGennaro Ciliberto
Sep 8, 2015·Vaccines·Pier-Luigi LolliniElena Quaglino
Jul 16, 2014·Expert Opinion on Biological Therapy·Federica CavalloGennaro Ciliberto
Dec 3, 2014·Seminars in Oncology·Mary L Disis
Oct 26, 2012·Veterinary and Comparative Oncology·J A ImpellizeriL Aurisicchio
Apr 29, 2015·Biotechnology Journal·Héla Kallel, Amine A Kamen
Sep 18, 2013·Biochemical and Biophysical Research Communications·Keng-Hsueh LanKeng-Li Lan
May 3, 2014·Oncoimmunology·Luigi AurisicchioGennaro Ciliberto
Dec 9, 2014·Human Vaccines & Immunotherapeutics·Maria TagliamonteLuigi Buonaguro
Apr 10, 2013·Gene·Anna KozłowskaAndrzej Mackiewicz
May 29, 2016·Pharmacology & Therapeutics·Angeliki Tiptiri-KourpetiKaterina Chlichlia
Nov 5, 2016·The Veterinary Journal·J ImpellizeriD M Soden
Aug 10, 2016·Journal of Clinical Gastroenterology·Cristina Jimenez-LunaOctavio Caba
Aug 23, 2019·Biomedicines·Brennetta J CrenshawQiana L Matthews
May 30, 2020·Cell Research·Yonina R Murciano-GoroffJedd D Wolchok
May 26, 2017·Biomedicines·Silvia Martin LluesmaLana E Kandalaft
Jun 28, 2018·Cancer Immunology, Immunotherapy : CII·Roberto RuiuLaura Conti
Dec 13, 2018·Journal of Translational Medicine·Joseph A ImpellizeriLuigi Aurisicchio
Aug 11, 2017·Expert Review of Clinical Immunology·Hila YousefiNima Rezaei
Aug 9, 2020·Nature Reviews. Drug Discovery·Alexandre HarariLana E Kandalaft
Jan 22, 2019·Journal of Immunology Research·Ren-You PanShuen-Iu Hung
Dec 8, 2020·Journal of Immunology Research·Yuka Igarashi, Tetsuro Sasada
Apr 17, 2021·Neuro-oncology Advances·Hannah E OlsenJoshua D Bernstock
May 19, 2021·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Neda RahimianHamed Mirzaei
Jul 3, 2021·Vaccines·Rani ChudasamaKhaldoun Almhanna

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.